Please assess the completion status of the following clinical trial:

Trial Title: A Study of Bermekimab in Patients With Hidradenitis Suppurativa

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent provided by the patient.~* Male or female, age 18 years or greater.~* For group A, patients must have received and failed anti-TNF therapy.~  * For Group B, patients must not have received any prior treatment with any anti-TNF therapy.~ * Patients who have received 200 mg dose of bermekimab in this study (previous version(s)) are eligible to begin receiving 400 mg dose starting with the patient's next scheduled visit for the remainder of his/her treatment plan.~* Diagnosis of HS for at least 1 year prior to screening.~* HS affecting at least two distinct anatomic areas, one of which is Hurley II or III stage.~* A total body count of abscesses and inflammatory nodules (AN) of at least 3~* Full understanding of the procedures of the study protocol and willingness to comply with them.~* In case of female patients of childbearing potential, willingness to use one method of contraception of high efficacy during the entire study period. This method can be intake of hormonal contraceptives or the use of one of the following: condoms, diaphragm or an intrauterine device. Women of non-childbearing potential include those considered to have a medical history that indicates that pregnancy is not a reasonable risk, including post-menopausal women and those with a history of hysterectomy.~Exclusion Criteria:~* Age below 18 years.~* Receipt of oral antibiotic treatment for HS within 28 days prior to screening.~* Receipt of prescription topical therapies for the treatment of HS within 14 days prior to screening, and/or systemic therapies for HS (immunosuppressants, corticosteroids, retinoids, or hormonal therapies) within 28 days prior to screening.~* History of treatment with bermekimab for any reason, EXCEPT patients previously treated with 200 mg bermekimab dose in the previous version(s) of this study.~* History of severe allergic or anaphylactic reactions to human, humanized, chimeric, or murine monoclonal antibodies.~* Has received a live (attenuated) vaccine over the 4 weeks prior to screening.~* New intake of opioid analgesics starting within 14 days prior to screening.~* Major surgery (requiring general anesthesia or respiratory assistance) within 28 days prior to Visit 1, Day 0 of start of study drug.~* Hepatic dysfunction defined as any value of transaminases or of γ-glutamyl transpeptidase (γGT), or of total bilirubin \> 3 x upper normal limit~* Stage C Child-Pugh liver cirrhosis.~* Chronic infection by the human immunodeficiency virus (HIV), hepatitis B virus (HBV) and/or hepatitis C virus (HCV).~* Neutropenia defined as \<1,000 neutrophils/mm3.~* Pregnancy or lactation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 400mg cohort, no prior treatment with anti-TNF agent(s) (Type: EXPERIMENTAL): N=10 patients that have had no prior treatment with biological agents that block TNF will receive a total of 13 X 400mg subcutaneous injections of bermekimab. Dosing will occur weekly for 12 weeks, inclusive of visit 1 and visit 13.
- 400 mg cohort, prior treatment with anti-TNF agent(s) (Type: EXPERIMENTAL): N=10 patients that have failed anti-TNF therapy will receive a total of 13 X 400mg subcutaneous injections of bermekimab. Dosing will occur weekly for 12 weeks, inclusive of visit 1 and visit 13.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete